Compared to single-target therapies such as IL-17 inhibitors or PDE4 inhibitors, the multi-target nature of SHTLS, as inferred from the network pharmacology and confirmed through in vitro/in vivo assays, supports its potential as a broad-spectrum therapeutic candidate for psoriasis. This evidence concerns the gene PDE4A and psoriasis.